Official Title
Adjuvant Use of Ivermectin To Hydroxychloroquine and Azithromycin in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study
Brief Summary

Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with pneumonia using Ivermectin with hydroxychloroquine compared to HCQ

Detailed Description

Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with pneumonia using Ivermectin 0.2mg/kg (12 mg adult dose ) single dose at once repeated after 1 week combined with hydroxychloroquine 400mg daily compared to HCQ 400 daily plus placebo single one dose repeated after 1 week.

Recruiting
COVID 19

Drug: Ivermectine
Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
Ivermectin + Hydroxychloroquin+ Azithromycin
Other Name: Ivermectin

Drug: Hydroxychloroquine Sulfate
Hydroxychloroquine Sulfate 400mg/daily
Ivermectin + Hydroxychloroquin+ Azithromycin
Placebo+ Hydroxychloroquin+ azithromycin
Other Name: Hydroxychloroquin

Drug: Placebos
(0.2 mg /kg=12 mg ) lactose single dose at once/ weekly
Placebo+ Hydroxychloroquin+ azithromycin
Other Name: Lactose

Drug: Azithromycin 500 mg
Azithromycin capsules 500mg daily
Ivermectin + Hydroxychloroquin+ Azithromycin
Placebo+ Hydroxychloroquin+ azithromycin
Other Name: Aithromycin

Eligibility Criteria

Inclusion Criteria:

-1. Patients with age above 18 years and any gender with definite Dx of covid19 and
pneumonia in the ward according to the clinical, laboratory, and imaging criteria.

2. Understands and agrees to comply with planned study procedures.

Exclusion Criteria:

1. Patients with hypersensitivity or severe adverse effects to Ivermectin

2. Renal impairment

3. Hepatic impairment.

4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)

5. Breast feeding.

6. Patient with covid 19 positive and mild no pneumonia

7. Children under the age of five or those who weigh less than 15 kilograms

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Iraq
Contacts

Faiq I Gorial, Professor
009647801730696
faiqig@yahoo.com

Faiq I Gorial, Professor
Principal Investigator
University of Baghdad

~

Jawad I. Rasheed
Study Chair
Arab Board for Health Specialiazation in Iraq

University of Baghdad
NCT Number
MeSH Terms
Azithromycin
Hydroxychloroquine
Ivermectin